


Medicare Increases Hospital Outpatient and ASC Payment for LimFlow TADV

Effective January 1, 2026, Medicare reassigned the LimFlow TADV procedure (CPT 0620T) from New Technology APC 1579 to New Technology APC 1580, which has an average payment amount of \$45,000 in the hospital outpatient department (HOPD) and an average payment of \$39,620 in the ambulatory surgical center (ASC).

This positive reassignment represents a 29% increase in hospital outpatient patient and a 25% increase in ASC payment for LimFlow TADV from 2025. Additionally, the facility payment for LimFlow TADV is not subject to multiple procedure discounting. Medicare finalized these positive updates in the 2026 Medicare Hospital Outpatient Prospective Payment System Rule released on Friday, November 21, 2025.

YoY Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) National Average Medicare Payment



As a reminder, effective October 1, 2024, hospital inpatient LimFlow TADV cases are eligible for an incremental payment of up to \$16,250 from Medicare in addition to the applicable MS-DRG payment for the case. This incremental reimbursement is called a “New Technology Add-on Payment” or NTAP. More information is available at: <https://limflow.com/us/reimbursement-resources>.

Sources:
 Medicare Outpatient Hospital Rates effective January 1, 2026 through December 31, 2026.; Source: CY 2025 OPPS Final Rule; hospital impact file, Addendum A
 Medicare ASC Rates effective January 1, 2026 through December 31, 2026.; Source: CY 2026 ASC Final Rule; Addendum AA
 LimFlow NTAP finalized in FY 2026 IPPS Final Rule (CMS-1808-F).

Disclaimer: The coding and payment information contained in this document is publicly available from third party sources, and Inari Medical is providing it for general informational purposes only. The payments and/or costs are not all-inclusive and is neither intended to nor does it constitute legal, reimbursement, or business advice. The information is not a promise or guarantee by Inari Medical regarding actual costs or payment rates that providers will receive for any given service. Site of service decisions (e.g., inpatient or outpatient) are based on medical necessity and should be determined by the physician in consultation with the patient and consistent with any payer guidelines or licensing provisions. If providers have questions about coverage, coding, or payment, providers should consult the specific payers. The Centers for Medicare and Medicaid Services (CMS) website is available at <https://www.cms.gov/Medicare/Medicare.html>

Important Safety Information: LimFlow System and LimFlow Stent Grafts Intended Use/Indications for Use: The LimFlow System and LimFlow Stent Grafts are indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. Contraindications: Patients with deep venous thrombus in target vein; Patients with uncorrected bleeding disorders or patients who cannot receive anticoagulation or antiplatelet aggregation therapy. Warnings and Precautions: Use in patients with concomitant hepatic insufficiency has not been evaluated; Use in patients with poor cardiac output, e.g., NYHA Class IV, has not been evaluated; Use in pregnant and breastfeeding women has not been evaluated; Implanting the device in the distal half of the calcaneus may result in stent fracture. Adverse Events: Acute renal impairment requiring dialysis; Cardiac arrest, Death, Embolization, Graft rupture, trans-graft leak, site leak; Hematoma; Insufficient blood flow to foot; Ischemia; Myocardial infarction; Occlusion; Pain; Peripheral edema; Procedural bleeding; Restenosis of stented segment; Sepsis / Infection; Stent damage, implant migration; Stent graft fracture; Stent graft misplacement, deformation, or migration; The need for surgical or endovascular interventions to rectify an access site problem; Thrombosis; Vessel dissection, perforation, injury; Vessel spasm. Please reference product Instructions for Use for more information regarding indications, warnings, precautions, contraindications, and adverse events. LimFlow ARC Intended Use/Indications for Use: The LimFlow ARC is intended to facilitate placement and positioning of guidewires and catheters within the peripheral vasculature. The LimFlow ARC is not intended for use in the coronary or cerebral vasculature. LimFlow V-Ceiver Intended Use/Indications for Use: The LimFlow V-Ceiver is intended for use in the cardiovascular system to manipulate and retrieve guidewires specified in the IFU. LimFlow Vector Intended Use/Indications for Use: The LimFlow Vector is intended for the treatment of vascular disorders and more particularly for excising or disrupting venous valves.
 Important Information: Prior to use, refer to the Instructions for Use for indications, contraindications, suggested procedure, warnings, adverse events, and precautions.
 Caution: Federal (USA) law restricts these devices to sale by or on the order of a licensed healthcare practitioner.
 All trademarks and copyrights are property of their respective owners. LimFlow is a proud member of the Inari Medical Family.